Fig. 1From: A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumorsStudy schema. After registration, participants had a lead-in period of troriluzole monotherapy for 2Â weeks to assess tolerance. Nivolumab was added at Week 1 and infusions were every 2Â weeks in combination with troriluzole. Tumor assessments were performed by CT scan at baseline, Week 6, Week 12 and every 12Â weeks for a year (not shown, schema is truncated for clarity)Back to article page